Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Capital Expenditures (2022)

BioXcel Therapeutics has reported Capital Expenditures over the past 1 years, most recently at $19000.0 for Q2 2022.

  • Quarterly results put Capital Expenditures at $19000.0 for Q2 2022, changed N/A from a year ago — trailing twelve months through Sep 2023 was $19000.0 (changed N/A YoY), and the annual figure for FY2023 was $20000.0, down 85.61%.
  • Capital Expenditures for Q2 2022 was $19000.0 at BioXcel Therapeutics, down from $120000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for BTAI hit a ceiling of $120000.0 in Q1 2022 and a floor of $19000.0 in Q2 2022.